| | Therapeutic agent (trade name) | Cytokine target | Treated disease |
| | Infliximab (Remicade) | TNF-α | Crohn’s disease, ulcerative colitis, psoriatic arthritis, rheumatoid arthritis, plaque psoriasis, and ankylosing spondylitis | | Adalimumab (Humira) | Crohn’s disease, ulcerative colitis, psoriatic arthritis, rheumatoid arthritis, psoriasis, juvenile idiopathic arthritis, hidradenitis suppurativa, and uveitis | | Certolizumab (Cimzia) | Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and nonradiographic axial spondyloarthritis | | Golimumab (Simponi) | Ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis | | Canakinumab (Ilaris) | IL-1β | Cryopyrin-associated periodic syndromes, juvenile idiopathic arthritis, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and familial Mediterranean fever | | Daclizumab (Zinbryta) | IL-2R | Multiple sclerosis | | Dupilumab (Dupixent) | IL-4R | Atopic dermatitis and asthma | | Mepolizumab (Nucala) | IL-5 | Severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis | | Reslizumab (Cinqair) | Severe eosinophilic asthma | | Siltuximab (Sylvant) | IL-6 | Castleman disease | | Tocilizumab (Actemra) | IL-6R | Rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, giant cell arteritis, and cytokine release syndrome | | Sarilumab (Kevzara) | Rheumatoid arthritis | | Guselkumab (Tremfya) | IL-23 p19 subunit | Plaque psoriasis | | Tildrakizumab (Ilumya) | Plaque psoriasis | | Ustekinumab (Stelara) | IL-12/IL-23 p40 subunit | Crohn’s disease, psoriatic arthritis, and psoriasis | | Ixekizumab (Taltz) | IL-17A | Plaque psoriasis and psoriatic arthritis | | Secukinumab (Cosentyx) | IL-17A/F | Plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis | | Brodalumab (Siliq) | IL-17R | Plaque psoriasis |
|
|
